Intervacc is trading 3.18% down at €0.08, with no confirmed company-specific catalyst identified.
- No new announcement or clearly disclosed catalyst was found for August 26, 2026; the latest material disclosure was the January–June interim report released August 20.
- Search coverage identifies the Q2 report as the latest company news, leaving the decline unattributed to earnings, regulatory decisions, or another confirmed event.
- Trading was closed when assessed; reliable volume data was unavailable, and positive biotech-sector context does not clearly explain the decline.